SG10202009598VA - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith - Google Patents
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithInfo
- Publication number
- SG10202009598VA SG10202009598VA SG10202009598VA SG10202009598VA SG10202009598VA SG 10202009598V A SG10202009598V A SG 10202009598VA SG 10202009598V A SG10202009598V A SG 10202009598VA SG 10202009598V A SG10202009598V A SG 10202009598VA SG 10202009598V A SG10202009598V A SG 10202009598VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- aminopurine compounds
- treatment therewith
- substituted aminopurine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202009598VA true SG10202009598VA (en) | 2020-10-29 |
Family
ID=55632334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702759XA SG11201702759XA (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| SG10202009598VA SG10202009598VA (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702759XA SG11201702759XA (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (ja) |
| EP (2) | EP3822274B1 (ja) |
| JP (4) | JP6884701B2 (ja) |
| KR (2) | KR20230035424A (ja) |
| CN (2) | CN113248506A (ja) |
| AR (1) | AR102171A1 (ja) |
| AU (2) | AU2015328414B2 (ja) |
| CA (1) | CA2963639C (ja) |
| CL (1) | CL2017000820A1 (ja) |
| CO (1) | CO2017003838A2 (ja) |
| CY (1) | CY1124173T1 (ja) |
| DK (1) | DK3204386T3 (ja) |
| EA (1) | EA201790779A1 (ja) |
| EC (1) | ECSP17026210A (ja) |
| ES (1) | ES2871142T3 (ja) |
| HR (1) | HRP20210656T1 (ja) |
| HU (1) | HUE054694T2 (ja) |
| IL (2) | IL251566B (ja) |
| LT (1) | LT3204386T (ja) |
| MX (2) | MX2017004600A (ja) |
| NZ (2) | NZ767954A (ja) |
| PL (1) | PL3204386T3 (ja) |
| PT (1) | PT3204386T (ja) |
| RS (1) | RS61884B1 (ja) |
| SG (2) | SG11201702759XA (ja) |
| SI (1) | SI3204386T1 (ja) |
| TW (1) | TW201629063A (ja) |
| WO (1) | WO2016057370A1 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230035424A (ko) * | 2014-10-06 | 2023-03-13 | 시그날 파마소티칼 엘엘씨 | 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CN107567450B (zh) | 2015-03-18 | 2020-03-13 | 百时美施贵宝公司 | 用作tnf抑制剂的杂环化合物 |
| JP6793658B2 (ja) | 2015-03-18 | 2020-12-02 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 |
| MX2017011434A (es) | 2015-03-18 | 2018-01-25 | Squibb Bristol Myers Co | Compuestos heterociclicos triciclicos sustituidos. |
| AU2016297784B2 (en) | 2015-07-24 | 2020-12-24 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| EP3331889B1 (en) | 2015-08-03 | 2020-09-23 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| EP3436018A4 (en) * | 2016-04-01 | 2019-11-13 | Signal Pharmaceuticals, LLC | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF |
| DK3436019T3 (da) * | 2016-04-01 | 2021-10-11 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf |
| CN109476696B (zh) * | 2016-06-02 | 2022-06-10 | 细胞基因公司 | 动物及人抗锥虫和抗利什曼原虫剂 |
| CN109563095B (zh) * | 2016-06-02 | 2021-10-29 | 细胞基因公司 | 动物和人抗疟剂 |
| KR20200061363A (ko) * | 2017-10-04 | 2020-06-02 | 셀진 코포레이션 | 시스-4-[2-｛[(3ｓ,4ｒ)-3-플루오로옥산-4-일]아미노｝-8-(2,4,6-트리클로로아닐리노)-9ｈ-퓨린-9-일]-1-메틸사이클로헥산-1-카르복스아미드의 제조 공정 |
| AU2018345647A1 (en) | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
| WO2022002118A1 (zh) * | 2020-07-01 | 2022-01-06 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7521446B2 (en) * | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US20090215744A1 (en) | 2005-11-18 | 2009-08-27 | Astrazeneca Ab | Solid Formulations |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| EP2076516B1 (en) | 2006-10-27 | 2013-12-11 | Signal Pharmaceuticals LLC | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| US8491930B2 (en) | 2008-04-23 | 2013-07-23 | Farmasierra Manufacturing, S.L. | Pharmaceutical formulation containing ibuprofen and codeine |
| US20130034495A1 (en) | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| KR20230035424A (ko) * | 2014-10-06 | 2023-03-13 | 시그날 파마소티칼 엘엘씨 | 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| DK3436019T3 (da) | 2016-04-01 | 2021-10-11 | Signal Pharm Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf |
-
2015
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko active Application Filing
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 MX MX2017004600A patent/MX2017004600A/es unknown
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 NZ NZ767954A patent/NZ767954A/en unknown
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active IP Right Grant
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en active Application Filing
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 NZ NZ730753A patent/NZ730753A/en unknown
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-04-26 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277069B (en) | Modified aminopurine compounds, their compositions and methods of treatment with them | |
| IL262007A (en) | Modified aminopurine compounds, their compositions and methods of treatment using them | |
| HK1254525A1 (zh) | 治療組合物、組合和使用方法 | |
| IL266560A (en) | Endophytes, related preparations and methods of using them | |
| IL246252A0 (en) | Diaminopyrimidyl derivative compounds, their compositions and methods of treatment | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
| ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
| HK1232137A1 (zh) | 治療化合物和組合物 | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| EP3207048A4 (en) | Compositions and methods of treating muscular dystrophy | |
| HK1259372A1 (zh) | 治療化合物、其組合物及使用方法 | |
| SG11201609254YA (en) | Therapeutic placental compositions, methods of making and methods of use | |
| HK1255221A1 (zh) | 使用卡多曲組合物進行治療的方法 | |
| PL2998311T3 (pl) | Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
| HK1258765A1 (zh) | 治療性化合物、組合物和它們的使用方法 | |
| HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
| ZA201608775B (en) | Hair treatment composition | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof | |
| GB201418272D0 (en) | Composition & methods of treatment | |
| GB201418268D0 (en) | Composition & methods of treatment |